Challenges in reporting pathogenic/potentially pathogenic variants in 94 cancer predisposing genes - in pediatric patients screened with NGS panels

[1]  Gregory M. Cooper,et al.  CADD: predicting the deleteriousness of variants throughout the human genome , 2018, Nucleic Acids Res..

[2]  S. Puig,et al.  Prevalence of pathogenic/likely pathogenic variants in the 24 cancer genes of the ACMG Secondary Findings v2.0 list in a large cancer cohort and ethnicity-matched controls , 2018, Genome Medicine.

[3]  A. Borkhardt,et al.  Penetrance and Expressivity in Inherited Cancer Predisposing Syndromes. , 2018, Trends in cancer.

[4]  J. Mi,et al.  Secondary findings in 421 whole exome-sequenced Chinese children , 2018, Human Genomics.

[5]  D. Hsiehchen,et al.  Nearing saturation of cancer driver gene discovery , 2018, Journal of Human Genetics.

[6]  M. Wagenmann,et al.  Mutational and Functional Analysis of FANCB as a Candidate Gene for Sporadic Head and Neck Squamous Cell Carcinomas. , 2018, Anticancer research.

[7]  B. Koenig,et al.  Understanding variations in secondary findings reporting practices across U.S. genome sequencing laboratories , 2018, AJOB empirical bioethics.

[8]  W. Chung,et al.  The impact of hereditary cancer gene panels on clinical care and lessons learned , 2017, Cold Spring Harbor molecular case studies.

[9]  K. Sénécal,et al.  Reporting practices for unsolicited and secondary findings from next‐generation sequencing technologies: Perspectives of laboratory personnel , 2017, Human mutation.

[10]  Keith Nykamp,et al.  Pathogenic variant burden in the ExAC database: an empirical approach to evaluating population data for clinical variant interpretation , 2017, Genome Medicine.

[11]  W. Chung,et al.  Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.

[12]  Joshua L. Deignan,et al.  A survey of current practices for genomic sequencing test interpretation and reporting processes in US laboratories , 2016, Genetics in Medicine.

[13]  Carla L. Fisher,et al.  “I Don’t Want to Be an Ostrich”: Managing Mothers’ Uncertainty during BRCA1/2 Genetic Counseling , 2017, Journal of Genetic Counseling.

[14]  E. Friedman,et al.  The risk for developing cancer in Israeli ATM, BLM, and FANCC heterozygous mutation carriers. , 2016, Cancer genetics.

[15]  James Y. Zou.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[16]  Gert Matthijs,et al.  Guidelines for diagnostic next-generation sequencing , 2015, European Journal of Human Genetics.

[17]  F. Johnson,et al.  Who decides and what are people willing-to-pay for whole genome sequencing information? , 2016, Genetics in Medicine.

[18]  S. Narod,et al.  Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel , 2016, Breast Cancer Research and Treatment.

[19]  Li Ding,et al.  Germline Mutations in Predisposition Genes in Pediatric Cancer. , 2015, The New England journal of medicine.

[20]  S. Syngal,et al.  Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome. , 2015, Gastroenterology.

[21]  Gabrielle M. Christenhusz,et al.  Towards a European consensus for reporting incidental findings during clinical NGS testing , 2015, European Journal of Human Genetics.

[22]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[23]  Brigitte Rack,et al.  Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Hopper,et al.  Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study , 2014, Breast Cancer Research.

[25]  J. Friedman,et al.  Paternalism and the ACMG recommendations on genomic incidental findings: patients seen but not heard , 2013, Genetics in Medicine.

[26]  Joshua L. Deignan,et al.  ACMG clinical laboratory standards for next-generation sequencing , 2013, Genetics in Medicine.

[27]  Marc S. Williams,et al.  ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.

[28]  Yuhki Yanase,et al.  Germline mutation in ATR in autosomal- dominant oropharyngeal cancer syndrome. , 2012, American journal of human genetics.

[29]  T. Dörk,et al.  Nonsense mutation p.Q548X in BLM, the gene mutated in Bloom’s syndrome, is associated with breast cancer in Slavic populations , 2012, Breast Cancer Research and Treatment.

[30]  Lucia A. Hindorff,et al.  Genetic architecture of cancer and other complex diseases: lessons learned and future directions. , 2011, Carcinogenesis.

[31]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[32]  Steven S. Chang,et al.  Inactivation of the Tumor Suppressor Genes Causing the Hereditary Syndromes Predisposing to Head and Neck Cancer via Promoter Hypermethylation in Sporadic Head and Neck Cancers , 2010, ORL.

[33]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[34]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[35]  Glyn Elwyn,et al.  Process and outcome in communication of genetic information within families: a systematic review , 2007, European Journal of Human Genetics.

[36]  C. Mathew,et al.  Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer , 2007, Nature Genetics.

[37]  Arto Mannermaa,et al.  RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. , 2005, Carcinogenesis.

[38]  Charis Eng,et al.  Highly penetrant hereditary cancer syndromes , 2004, Oncogene.